Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/88—Liliopsida (monocotyledons)
  • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
  • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
  • A61K36/835—Aquilaria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/88—Liliopsida (monocotyledons)
  • A61K36/906—Zingiberaceae (Ginger family)
  • A61K36/9064—Amomum, e.g. round cardamom

Definitions

• the plant mixture preparation has three characteristic basic effects.
• the three effects combine to form a spectrum of activity which comprises components of transquilizers, antidepressants and vegetative regulating agents.
• the plant mixture according to the invention takes effect in two phases. In the first phase, which begins relatively quickly (days 1 to 5), anxiety and tension are released without impairing physical and mental performance. In the second phase (7th to 14th day) there is a change in mood, which the patients experience as inner liberation. The depressed mood subsides and the patients show more self-confidence and activity.
• the main target group are anxious, hypochondriacal and depressed-mood patients, in whom the disturbance of the mental state is expressed by insomnia, anxiety, inner restlessness, tension, nervous exhaustion and by "minus symptoms”.
• the invention is illustrated by the following example.
• the individual starting materials which are ground independently to form fine powder, are mixed with one another in order to give the mixture of substances in homogeneous form.
• the following active ingredient composition of the pharmaceutical preparation has proven to be particularly balanced and optimized for the treatment of depression: Wormwood herb (Artemisia absinthium) 150 mg
• Onosma flowers (Flores onosma brateatum) 90 mg filled in capsules of the Great OO.
• the patients were initially treated with the substance according to the invention for three weeks. After this time, the treatment was randomized and continued double blind with either placebo (similar looking capsules) or verum for another 2 weeks. If the clinical picture deteriorated during this 5-week treatment or remained unchanged during the first 2 weeks, these patients were withdrawn from the study. Patients at risk of suicide were excluded from the study from the outset.
• the disgruntled patient is still emotionally agile. This type of depression is most commonly seen in medical consultations. The states of blemish often appear together with anxiety.
• 160 patients were treated with the substance mixture according to the invention (2 to 3 g daily) for 4 weeks. All patients had to meet the DSM-i ⁇ criteria of "Major Depressive Disorder" (Diagnostic Statistical Manual, American Psychiatry Association 1978) in order to be accepted into the study. The study was carried out in the author's practice according to the guidelines of the new AMG. The severity of the mood was determined using the self-evaluation scales and the Hamilton Depression Scale (HDRS). There was a clear improvement in the first week of treatment. After 4 weeks, less than 10% of the patients showed no or only moderate effects. The results again demonstrate the good effect of the mixture in the treatment of depressed mood states.
• HDRS Hamilton Depression Scale
• Depression the appearance of which is characterized by the predominance of physical, especially vegetative symptoms and in which the psychological phenomena are pushed into the secondary role, are called vegetative, vegetative-dystonic or also somatized depression.
• the depressive symptoms are often not diagnosed in such patients because the patients are so overwhelmed by the power of somatic disorders that they only complain to the doctor about physical complaints.
• Pathological anxiety a very common occurrence, is very often treated with sedative anxiolytics - especially with benzodiazepines. Severe dose increases are often tolerated by the doctor and, at the patient's request, the prescription extends over long, sometimes over indefinite periods of time, so that iatrogenic drug addiction and drug addiction has become a problem. To check if that
• the decisive factor in the inclusion of a patient in the study was the diagnosis of "pathological fear”.
• the examined patient population was divided into four symptom-oriented subgroups
• Group I This group included the patients in whom the pathological anxiety expressed primarily on a psychological level, be it in the form of a permanent state or seizure, provided that the seizures were not triggered by any special reason and psychological manifestations of the anxiety prevailed. This group consisted of 20 patients (see Table 2).
• Group II This group consisted of 15 patients with phobic anxiety, whose anxiety exacerbations, which manifested themselves primarily in psychological or somatic symptoms, appeared to be triggered by certain stimuli.
• Group III This group consisted of 20 patients in whom anxiety was accompanied by a depressed mood, often with feelings of loss and impaired ability to concentrate as well as lack of drive and lack of energy.
• Group IV This group of 25 patients mainly expressed fear in somatic symptoms that were either general or more cardiovascular, respiratory, gastrointestinal, urogenital or vegetative in nature.
• the severity of fear was determined using the Hamilton 14-point fear scale.
• the total number of points 1 to 6 and point 14 were compared to the total number of points 7 to 13.
• the patients were assigned to the "psychological" or "somatic" group depending on the type of symptom that reached the higher sum.
• Hamilton's anxiety scale was evaluated weekly before the start of treatment and in the first four weeks of the study and after completion of therapy, and was repeated after three months at the latest. None of the patients received additional psychotropic drugs during the duration of the study, but the previous one became somatic Continuous treatment continued as additional treatment.
• the dosage ranged from 3 to 8 capsules per day depending on the patient's response. If the patient's condition worsened during treatment with the mixture of substances according to the invention or if there was no appreciable improvement during the first three weeks of treatment, the patient was removed from the study. The results are summarized in Table 1
• the mixture of substances according to the invention represents a useful and useful combination for the treatment of various anxiety states. Satisfactory clinical improvement was achieved in a short period of time in about two thirds of the patients - a result that can be compared with the results of the benzodiazepine therapy. The extent of the improvement was expressed in the decrease in the mean total value of anxiety calculated with the Hamilton scale to one third of the initial value before treatment and in the self-assessment by the patients. No side effects were observed. Patients with somatic anxiety symptoms responded better to therapy than patients with phobias. But also in the category anxiety with accompanying depression there was a clear improvement in more than two thirds of the cases.
• the substance mixture differs from the benzodiazepines.
• the difference from benzodiazepines in the present context was most evident in the patients in whom the medication had to be continued for three months or more. After the end of therapy, none of the patients developed symptoms that could suggest withdrawal symptoms.
• the self-assessment of the patients showed a sleep-inducing effect in 85% of the patients
• the average sleep time before treatment started was over an hour, on the 5th day of treatment only about 15 minutes and after two weeks about 10 minutes.
• the dry herb contains 0.25-1.32% essential oil, absinthin, anabsin, anabsinthin, artabsin and matricin.
• the essential oil contains thujone and thujyl alcohol as well as a number of other terpenes derivatives.
• a good commercial drug should have an absorbency content of at least 0.2% (determined by spectrophotometry), which corresponds to a bitter value of approx. 15,000
• the herb is used among other things as an appetizer, as a worming agent and as
• Citral approx. 1% eugenol, 1-linaool, farnesol, approx. 3-5% esters of the above alcohols, 15-30%
• the rose petals are found as astringency, in diarrhea, in the perfume industry and as
• Dried, powdered wood is used in Indian folk medicine as a carminative, tonic, astringent for diarrhea and vomiting, as a mild stimulant and in the perfume industry.
• Ferments such as nuclease, urease, diastase and other protolytic and emulsifying

Landscapes

• Health & Medical Sciences (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Alternative & Traditional Medicine (AREA)
• Biotechnology (AREA)
• Botany (AREA)
• Medical Informatics (AREA)
• Medicinal Chemistry (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicines Containing Plant Substances (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (1)

Family

ID=6356519

Family Applications (1)

Country Status (4)

Cited By (7)

Families Citing this family (5)

• 1988
  • 1988-06-14 DE DE19883820218 patent/DE3820218A1/de active Granted
• 1989
  • 1989-05-17 CH CH182389A patent/CH680649A5/de not_active IP Right Cessation
  • 1989-06-10 WO PCT/DE1989/000381 patent/WO1989012454A1/de not_active Ceased
  • 1989-06-10 EP EP19890906713 patent/EP0396638B1/de not_active Expired - Lifetime

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events